The structure of global supply chains is changing. This threatens the pharmaceutical security of the sitizens of European Union. It was visible during the first wave of the COVID-19 pandemic, which paralyzed the ability to keep the supply chain running. These very changes have shown how dependent we are from API* manufacturing in Asia.

In last years, 80%** of the active pharmaceutical ingredients, used in medicines and crucial to the manufacturing process of drugs in the EU, came from Asia. The Far East market ownes its position to lower costs of labor, energy and environmental protection. That results in a lower API production price, without affecting their certified quality. Pharmaceutical companies, by including in their medications active substances from Asia, make their medicines cheaper. Gaining in this same way the advantage over competitors who decided not to include imported substances.

However, what if the supply chain becomes disrupted?

The extended API storage is the best protection against the supply chain disruption.

This step will allow to maintain stability and continuity of business, to protect against supply chain disruption and, the most importantly, to deliver products continuously, especially during periods of fluctuating demand. This solution generates additional costs for the company, but from the invesment perspective is gaining higher suppliers interest.

It is necessary to remember that not every entity can store imported APIs.

In order to run this kind of warehouse, it is crucial to have appropriate space, a GDP certificate,,  and a manufacturing license which is issued by the Main Pharmaceutical Inspector. Neuca Group has the necessary infrastructure that meets all the requirements to store and distribute APIs.

—

*API (ang. Active Pharmaceutical Ingredient)
** Source: ProGenerika Study of API supply vulnerabilities for the European pharmaceutical industry, JULY 2021